Traditional Chinese medicine may reduce the dosage of systemic glucocorticoids in required patients with acute exacerbation of chronic obstructive pulmonary disease:study protocol for a randomized placebo-controlled trial

Hospital of Chengdu University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Patients who meet the diagnosis of phlegm-heat congested lung syndrome of AECOPD and need systemic glucocorticoid administration;
•2. COPD GOLD stage 3 or 4 (post-bronchodilator forced FEV1/FVC < 70% and FEV1 < 50% of predicted);
•3. Age from 40 to 65 years old and have symptomatic COPD (CAT scores >= 10), regardless of sex;
•4. Expected survival time >= 30 days;
•5. Patients and their families agree to participate and sign informed consent.

•1. Atypical bacterial infections, such as atypical pathogens and drug-resistant bacteria;
•2. Complicated with a severe tumor, unstable coronary heart disease, abnormal liver and kidney function, cerebrovascular accident, and other diseases;
•3. Other associated active or clinically significant respiratory diseases that have a significant impact on the study, such as active pulmonary tuberculosis, lung cancer, bronchiectasis, pulmonary hypertension, pulmonary interstitial disease, and other active lung diseases;
•4. Severe hypertension, diabetes, peptic ulcer, and other glucocorticoids contraindications;
•5. Patients who require invasive mechanical ventilation;
•6. Pregnant, lactating, and menstrual women;
•7. Patients with mental disorders who are unable to actively cooperate with treatment;
•8. Patients with a history of allergies to related drugs.

发起方

Hospital of Chengdu University of Traditional Chinese Medicine